MEDIUM confidence
Researched 2026-07-24 07:40 · profile: researcher
Programme Thesis
The DayOne Accelerator Program funds early-stage healthtech and pharma R&D ventures, providing mentorship and resources to accelerate innovation. It exists to bridge the gap between scientific discovery and commercial application, supporting startups that address critical healthcare challenges.
Selection Criteria
- Innovation and scientific merit of the product or technology
- Market potential and scalability of the business model
- Strength and expertise of the founding team
- Stage of development (pre-seed to early-stage preferred)
- Alignment with healthtech and pharma R&D focus
- Clarity of pitch deck and business plan
Past Winners / Cohort Profiles
Past cohorts typically include early-stage healthtech startups with validated prototypes or MVPs, often in digital health, diagnostics, or drug development. Named examples are not available from the page, but archetypes include teams with strong scientific foundations and clear commercial pathways.
Ideal Candidate Fingerprint
The ideal applicant is a pre-seed or seed-stage healthtech venture with a validated scientific breakthrough, a scalable product, and a founding team combining deep domain expertise with business acumen. The venture should have a clear path to market and demonstrate potential for significant impact in pharma R&D or healthcare delivery.
Recommended Framing
Eniola should position the CCT model and IMPRINT platform as a breakthrough healthtech innovation at the intersection of computational neuroscience and pharma R&D, emphasizing the validated 85.8% reduction in encoding probability and the platform's scalability for addiction-liability screening. Leverage endorsements from Kent Berridge and Samuel Gershman to underscore scientific credibility, and frame the venture as a pre-seed opportunity with a provisional patent and clear clinical trial architecture, aligning perfectly with the accelerator's focus on early-stage, high-impact healthtech.
Watch Out
The applicant is an independent researcher not yet enrolled in a PhD or MSc program, which may be seen as a lack of formal academic backing. Additionally, the venture is at a very early stage (pre-seed) with no revenue or user traction, which could be a competitive disadvantage against more mature startups. The lack of a co-founder with business experience may also be a concern.